|
gptkbp:instanceOf
|
antiviral drug
triazole
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J02AC03
|
|
gptkbp:brand
|
gptkb:Vfend
|
|
gptkbp:CASNumber
|
gptkb:137234-62-9
|
|
gptkbp:category
|
antifungal agent
azole antifungal
|
|
gptkbp:contraindication
|
co-administration with certain CYP3A4 substrates
hypersensitivity to voriconazole
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
gptkb:C16H14F3N5O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
voriconazole
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase
|
|
gptkbp:metabolism
|
gptkb:CYP2C9
gptkb:CYP2C19
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
58%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
skin rash
liver toxicity
visual disturbances
|
|
gptkbp:usedFor
|
treatment of invasive aspergillosis
treatment of candidemia
treatment of serious fungal infections
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
gptkb:CYP3A5
gptkb:Candida_tropicalis
gptkb:J02AC13
gptkb:Aspergillus_fumigatus
|
|
gptkbp:bfsLayer
|
6
|